Genomic Vision has obtained a new patent for its “Physical Characterization of Telomeres” method based on molecular combing

BAGNEUX, France, June 16, 2022-(BUSINESS WIRE)-Regulatory News:

Genomic Vision (FR0011799907-GV Qualified, PEA-PME) (Paris: GV)a biotechnology company that develops tools and services dedicated to the analysis and control of genome changes, today announced the successful publication of a patent on “Physical Characterization of Telomeres” (PCT).

The patent was granted by the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO) in June 2022. With this patent, Genomic Vision expands the portfolio of its inventions by providing a new dimension to use of proprietary molecular combing technology in the field of age -related diseases and the onset of certain cancers.

What are telomeres?

Telomers are protective regions located at the end of each chromosome. Whenever a cell divides, the telomeres become shorter. The time comes when the telomeres become so short that the cells can no longer divide and die. Because of this phenomenon, the demonstration of telomere contraction or loss has opened up a wide field of applications in biological and age-related diseases that could lead to a medical breakthrough to treat. chronic diseases and contribute to improving life expectancy.

What are PCT patent applications?

Thanks to this invention, Genomic Vision technology can not only be used to detect the physical length of telomeres, but also to determine regions of the genome that are close or not to telomeres; this is to associate diseases or biomarkers where recognition of telomere contraction or loss is essential.

Using artificial intelligence (AI), PCT applications can automatically detect signals and build an internal database.

Based on PCT’s patent, Genomic Vision’s overall approach will provide integrated bio-analytical tools in the following areas:

  • Age -related diseases;

  • Improving living conditions;

  • The study of telomere length in genome size;

  • Identification of biomarkers for diseases associated with specific chromosomes;

  • Help with early prognosis of diseases.

In the third quarter of 2021, Genomic Vision has launched its TeloSizer® service, an innovative tool to physically measure the size and distribution of telomeres to establish a correlation between telomere length and disease onset as well the severity of it. . This new patent provides valuable additional knowledge to determine how telomere length can serve, among other things, as a biomarker in medicine.

Dominique Remy-Renou, CEO of Genomic Vision said: “We are proud to have obtained this patent, which allows us to further protect our technology in various fields of application. Intellectual property policy is an integral part of our development strategy. and I want to thank our IP team for this success ”

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services focused on the analysis (structural and functional) of genome changes as well as on the quality and safety control of these changes, especially in editing technologies. of the genome and in the processes of bioproduction. . GENOMIC VISION’s proprietary tools based on DNA combing technology and artificial intelligence, provide the robust amount of measurements needed for reliable characterization of DNA changes in the genome. These tools are notably used to monitor DNA replication in cancer cells, for the early detection of cancers and for the diagnosis of genetic diseases. Based in Bagneux, in the Paris region, the company has approximately 30 employees. GENOMIC VISION is listed on the Euronext regulated market in Paris, Compartment C (Euronext: GV – ISIN: FR0011799907).

www.genomicvision.com

WARNING

This press release contains implicitly or explicitly forward-looking statements relating to Genomic Vision and its activities. Genomic Vision believes these statements are based on reasonable assumptions. However, no guarantee can be given regarding the achievement of the forecasts expressed in these statements that hope to be subject to risks, including those described in the “Risk Factors” section of the Universal Registration Document filed with the Autorité des Marchés Financiers (AMF) on April 14, 2022, under registration number D. 22-0293, updated by amendment filed with the Autorité des Marchés Financiers (AMF) on May 20, 2022, under number D .22-0293-A01, available on the company’s website (www.genomicvision.com) and changes in economic conditions, financial markets and markets in which Genomic Vision is located. The forward statements contained in this press release are also subject to risks that Genomic Vision is not aware of or that Genomic Vision has not considered the material as of this date. The realization of all or part of these risks may cause the actual results, financial conditions, performance or achievements of Genomic Vision to differ materially from the results, financial conditions, performances or achievements announced in these future statements.

This press release and the information contained therein do not constitute, nor should they be construed as an offer or invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe to part of Genomic Vision. in any country. Distribution of this press release in certain countries may be a violation of the legal provisions in force. People holding press releases must inform themselves of any local restrictions and comply with them.

Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20220616005853/en/

contacts

Genomic Vision
Dominique Remy-Renou
Chairman of the Board of Management
ganyan. : +33 1 49 08 07 51
investors@genomicvision.com

Communication by Ulysses
Press relations
Bruno Arabian
ganyan. : +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations
and Strategic Communication
ganyan. : +33 1 44 71 94 94
gv@newcap.eu

Leave a Comment